ArriVent and its Chinese development partner Allist reported that first-line firmonertinib monotherapy did not meet the blinded independent central review progression-free-survival endpoint in the global Phase 3 FURVENT study of EGFR exon 20 insertion…
Enliven reported FDA alignment on the design of ENABLE-2, a planned randomized Phase 3 trial of relcobatinib in previously treated chronic myeloid leukemia. The event specifies a testable pivotal comparison and endpoint but supplies…
Multiply Labs announced a $75 million Series B led by Patrick Soon-Shiong with NantWorks to expand robotic biologics manufacturing. The financing is material for a platform attempting to automate cell and gene therapy production,…
Genentech licensed worldwide rights to Alector’s preclinical AL050 program for $100 million upfront, as much as $1.17 billion in conditional milestones and tiered royalties. AL050 couples engineered GCase to a blood-brain-barrier carrier. The agreement…
CSL and Alentis entered a global collaboration to develop and promote lixudebart, an antibody against exposed claudin-1. CSL will make a $355 million initial payment, fund specified trials and may pay up to $1.2…
Prime Medicine dosed the first participant in its global Phase 1/2 study of PM577a, an LNP-delivered prime editor designed to correct ATP7B p.H1069Q in hepatocytes. This is a meaningful execution milestone for in vivo…
Shionogi agreed to acquire IntraBio for $2.0 billion upfront, adding the oral levacetylleucine franchise and a rare-neurology pipeline. Recent approvals establish a commercial base, while adoption, reimbursement and integration will determine whether the price…
The Nobel Assembly awarded the 2026 Prize in Physiology or Medicine to Karl Deisseroth, Peter Hegemann and Georg Nagel for discoveries concerning light-gated ion channels and optogenetics. The October 5 recognition marks the field-shaping…
Source-gap catch-up for a 5 October announcement. NeoGenomics appointed current president and COO Warren Stone to succeed Tony Zook as CEO on 4 January 2027. Zook will become executive chair; current chair Lynn Tetrault…
Evidence before optionality — a first-line label expansion backed by an 80% risk reduction led the week, large pharma wrote roughly $2.3 billion of upfront checks for early-stage modalities, and two programs that could…
